Sarepta Therapeutics, Inc.

NASDAQ:SRPT

Biotechnology

Healthcare
$14.53 +1.71%

+$0.29 today

Market cap
$1.56B
Beta
0.20
P/E (TTM)
27.8
EPS (TTM)
$0.62
52W Low $10.42High $25.32

Volume 1.86M

Average 3.08M

SRPT Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Sarepta Therapeutics, Inc.NASDAQ: SRPT

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of $10.59M rose 6.2% year over year, behind the +15.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 101.7% from the prior quarter. Over 3 fiscal years it compounded at +2.1% a year.

Context

  • Depreciation & amortization amounted to 2.0% of revenue in FY2025, unchanged from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +6.2% toward the trailing-twelve-month pace of +15.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$10.59M+101.7% QoQ
Last fiscal yearDec 2025
$44.52M+18.0% YoY
LTMMar 2026
$45.14M+15.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.2%——
1 year+18.0%——
3-year CAGR+2.1%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
44.52M USD
Year-over-year change
+18.0%
4-year CAGR
+4.0%

Depreciation & Amortization vs competitors

How SRPT compares with its peers on the latest reported figures

  • SRPT's LTM Mar 2026 depreciation & amortization of $45.14M is the 4th highest of the 11 companies compared; the peer median is $9.49M.
  • Its year-over-year change of +15.9% is the 3rd highest of 11, against a peer median of +2.6%.
  • Depreciation & amortization amounts to 2.1% of revenue for SRPT, versus a peer median of 5.5%.
SRPT Competitors Peer median
Depreciation & Amortization for SRPT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$1B +66925.2%+52.5%—
PTCTPTC Therapeutics, Inc.LTM Jun 2026$55.3M +97.1%-33.0%5.5%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$54.76M -3.1%+7.8%1.1%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$45.14M +15.9%+2.1%2.1%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$21.89M +6.2%+0.9%2.3%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$9.99M -2.7%+28.1%15.1%
WVEWave Life Sciences Ltd.LTM Mar 2026$8.99M +4.0%-4.3%12.5%
PEPGPepGen Inc.LTM Mar 2026$3.2M -40.7%+41.5%—
DYNDyne Therapeutics, Inc.LTM Jun 2026$2.15M +13.8%+6.8%—
SLDBSolid Biosciences Inc.LTM Mar 2026$1.62M -35.9%-12.1%—
DSGNDesign Therapeutics, Inc.LTM Mar 2026$620K +1.3%+10.1%—
Peer median (excluding SRPT) $9.49M+2.6%+7.3%5.5%

Competitors are the stored peer set for SRPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue701.89M933.01M1.24B1.9B2.2B
Cost of Revenue97.05M139.99M150.34M319.1M881.5M
Gross Profit604.84M793.02M1.09B1.58B1.32B
Gross Margin86.2%85.0%87.9%83.2%59.9%
Research & Development771.18M877.09M877.39M804.52M1.52B
Selling, General & Admin282.66M451.42M481.87M557.87M478.94M
Operating Expenses1.06B1.33B1.36B1.36B1.97B
Depreciation & Amortization38.02M41.86M44.4M37.72M44.52M
EBITDA(317.41M)(594.85M)(453.69M)316.89M(647.97M)
EBITDA Margin-45.2%-63.8%-36.5%16.7%-29.5%
Operating Income(459.71M)(536.2M)(267.82M)218.08M(657.77M)
Operating Margin-65.5%-57.5%-21.5%11.5%-29.9%
Interest Income511K27.72M85.97M71.77M19.57M
Interest Expense63.53M53.25M22.01M18.39M9.73M
Other Income / Expenses40.76M(153.76M)(252.27M)42.69M(44.45M)
Income Before Tax(418.95M)(689.96M)(520.1M)260.77M(702.23M)
Pre-Tax Margin-59.7%-73.9%-41.8%13.7%-31.9%
Income Tax Expense(168K)13.53M15.88M25.54M11.19M
Net Income(418.78M)(703.49M)(535.98M)235.24M(713.41M)
Net Margin-59.7%-75.4%-43.1%12.4%-32.5%
EPS (Basic)(5.15)(8.03)(5.80)2.47(7.13)
EPS (Diluted)(5.15)(8.03)(5.80)2.34(7.13)
Weighted Avg Shares81.26M87.56M92.4M95.08M104.79M
Weighted Avg Shares (Diluted)81.26M87.56M92.4M107.88M104.79M

Sarepta Therapeutics, Inc.

NASDAQ:SRPT

Intrinsic Alpha fair value

Locked

Current Price

$14.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.